Research Analysts Issue Forecasts for Trinity Biotech plc’s Q2 2024 Earnings (NASDAQ:TRIB)

Trinity Biotech plc (NASDAQ:TRIBFree Report) – Analysts at Sidoti Csr issued their Q2 2024 earnings per share (EPS) estimates for shares of Trinity Biotech in a research report issued to clients and investors on Wednesday, May 29th. Sidoti Csr analyst J. Sidoti anticipates that the company will post earnings of ($0.67) per share for the quarter. The consensus estimate for Trinity Biotech’s current full-year earnings is ($2.17) per share. Sidoti Csr also issued estimates for Trinity Biotech’s Q3 2024 earnings at ($0.60) EPS, Q4 2024 earnings at ($0.52) EPS, FY2024 earnings at ($2.17) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($1.04) EPS.

Separately, StockNews.com started coverage on Trinity Biotech in a research note on Monday. They issued a “buy” rating on the stock.

View Our Latest Report on Trinity Biotech

Trinity Biotech Price Performance

TRIB stock opened at $1.65 on Monday. The company has a market cap of $12.57 million, a P/E ratio of -0.59 and a beta of 1.24. Trinity Biotech has a 1 year low of $1.49 and a 1 year high of $5.50. The stock’s fifty day moving average price is $1.79 and its 200-day moving average price is $2.13.

Trinity Biotech (NASDAQ:TRIBGet Free Report) last issued its earnings results on Thursday, April 4th. The company reported ($0.68) EPS for the quarter. The business had revenue of $13.43 million during the quarter.

Trinity Biotech Company Profile

(Get Free Report)

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.

Further Reading

Earnings History and Estimates for Trinity Biotech (NASDAQ:TRIB)

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.